<?xml version='1.0' encoding='utf-8'?>
<document id="24993574"><sentence text="Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications." /><sentence text="Psoriasis is a chronic inflammatory skin disease condition that involves altered expression of a broad spectrum of proinflammatory cytokines which are associated with activation of T cells and proliferation of keratinocytes" /><sentence text=" Currently approved biological products for psoriasis treatment fall into two main classes: cytokine modulators and biologics targeting T cells" /><sentence text=" In psoriatic patients, elevated levels of proinflammatory cytokines are observed" /><sentence text=" Elevated proinflammatory cytokines can suppress some cytochrome P450 (CYP) enzymes, and the treatment of psoriasis with biological products can reduce proinflammatory cytokine levels" /><sentence text=" Therefore, the exposure of CYP substrate drugs is anticipated to be affected by the psoriasis disease resulting in a higher exposure than in healthy state (named disease-drug interaction) as well as by the biological treatments due to disease improvements resulting in a decrease in exposure (named disease-drug-drug interaction, disease-DDI)" /><sentence text=" However, the quantitative impact on CYP substrate exposure due to disease or due to treatment with biological products remains to be evaluated" /><sentence text=" The objective of the current review is to provide an overview of the therapeutic targets and cytokine-related pharmacodynamic effects of biological products in psoriasis treatment with a particular focus on their implications for disease-DDI" /><sentence text=" The clinical study design considerations for psoriasis disease-DDI evaluation are also discussed" /><sentence text="" /></document>